Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
KOD Kodiak Sciences
7.540
+0.150+2.03%
Post Mkt Price
7.510
-0.030-0.40%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
17.68% 79.48M 64.67% 92.07M 89.42% 95.77M 96.35% 267.05M
Selling and administrative expenses
54.36% 17.8M 74.43% 18.32M 91.66% 19.59M 73.71% 49.71M
-General and administrative expense
54.36% 17.8M 74.43% 18.32M 91.66% 19.59M 73.71% 49.71M
Research and development costs
10.13% 61.68M 62.42% 73.74M 88.85% 76.18M 102.39% 217.34M
Operating profit
-17.68% -79.48M -64.67% -92.07M -89.42% -95.77M -96.35% -267.05M
Net non-operating interest income expense
5,852.94% 2.02M 1,386.84% 1.13M -50.35% 71K -90.41% 276K
Non-operating interest income
4,970.00% 2.03M 1,301.23% 1.14M -48.99% 76K -89.73% 298K
Non-operating interest expense
-33.33% 4K 0.00% 5K -16.67% 5K -12.00% 22K
Other net income (expense)
1,764.00% 416K 1,731.58% 310K 59.38% -13K -732.35% -215K
Other non- operating income (expenses)
1,764.00% 416K 1,731.58% 310K 59.38% -13K -732.35% -215K
Income before tax
-14.09% -77.04M -62.26% -90.63M -89.72% -95.71M -100.60% -266.99M
Income tax
Net income
-14.09% -77.04M -62.26% -90.63M -89.72% -95.71M -100.60% -266.99M
Net income continuous Operations
-14.09% -77.04M -62.26% -90.63M -89.72% -95.71M -100.60% -266.99M
Minority interest income
Net income attributable to the parent company
-14.09% -77.04M -62.26% -90.63M -89.72% -95.71M -100.60% -266.99M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-14.09% -77.04M -62.26% -90.63M -89.72% -95.71M -100.60% -266.99M
Basic earnings per share
-13.08% -1.47 -61.11% -1.74 -86.73% -1.83 -77.32% -5.16
Diluted earnings per share
-13.08% -1.47 -61.11% -1.74 -86.73% -1.83 -77.32% -5.16
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
CEO: Dr. Victor Perlroth, M.D.
Market: NASDAQ
Listing Date: 10/04/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist